cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Gilead Sciences Inc
158 own
150 watching
Current Price
$83.73
$0.11
(0.13%)
logo-gild
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
104,997.42M
52-Week High
52-Week High
89.74
52-Week Low
52-Week Low
57.165
Average Volume
Average Volume
4.11M
Dividend Yield
Dividend Yield
0.04237
P/E Ratio
P/E Ratio
11.3194
iconMarket Capitalization104,997.42M
icon52-Week High89.74
icon52-Week Low57.165
iconAverage Volume4.11M
iconDividend Yield0.04237
iconP/E Ratio11.3194
What does the Gilead Sciences Inc do?
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East. The company's products include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis C virus and hepatitis B virus; hematology/oncology; cardiovascular; and inflammation/respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.
Read More
How much money does Gilead Sciences Inc make?
News & Events about Gilead Sciences Inc.
Zolmax
8days ago
Gilead Sciences (NASDAQ:GILD Get Rating) had its target price raised by Piper Sandler from $104.00 to $111.00 in a research report sent to investors on Thursday morning, The Fly reports. Piper Sandler currently has an overweight rating on the biopharmaceutical companys stock. A number of other ...
Benzinga
11days ago
Latest Ratings for GILD DateFirmActionFromTo Mar 2022BarclaysMaintainsUnderweight Mar 2022RBC CapitalMaintainsOutperform Feb 2022BMO CapitalDowngradesOutperformMarket Perform View More Analyst Ratings for GILD View the Latest Analyst Ratings read more...
Accesswire
11days ago
NORTHAMPTON, MA / ACCESSWIRE / January 19, 2023 / Dr. Hila Elinav burst into tears of joy when the Israeli Ministry of Health announced a sweeping new HIV screening policy for pregnant women in September.'It was a long-awaited, emotional moment,' says Hila, a member of the Israeli...
Stock Options Channel
12days ago
Investors in Gilead Sciences Inc (GILD) saw new options begin trading today, for the April 21st expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 93 days until expiration the newly trading contracts represent a possible ...
Accesswire
18days ago
NORTHAMPTON, MA / ACCESSWIRE / January 12, 2023 / Gilead Sciences Every time a serious new COVID-19 virus variant emerges, Gilead virologists Charlotte Hedskog and John Bilello, alongside their teams, mobilize as so-called 'variant hunters.'Their mission is to determine whether...
Frequently Asked Questions
Frequently Asked Questions
What is Gilead Sciences Inc share price today?
plus_minus_icon
Can Indians buy Gilead Sciences Inc shares?
plus_minus_icon
How can I buy Gilead Sciences Inc shares from India?
plus_minus_icon
Can Fractional shares of Gilead Sciences Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Gilead Sciences Inc stocks?
plus_minus_icon
What is today’s traded volume of Gilead Sciences Inc?
plus_minus_icon
What is today’s market capitalisation of Gilead Sciences Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Gilead Sciences Inc?
plus_minus_icon
What percentage is Gilead Sciences Inc down from its 52-Week High?
plus_minus_icon
What percentage is Gilead Sciences Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$83.73
$0.11
(0.13%)
logo-gild
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Bristol-Myers Squibb Co.
Bristol-Myers Squibb Co.
$72.45
$-0.54 (-0.74 %)
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
$321.45
$0.43 (0.13 %)
United Therapeutics Corporation
United Therapeutics Corporation
$259.68
$-4.55 (-1.72 %)
Zoetis Inc.
Zoetis Inc.
$165.18
$-3.06 (-1.82 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Bristol-Myers Squibb Co.
Bristol-Myers Squibb Co.
$72.45
$-0.54 (-0.74 %)
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
$321.45
$0.43 (0.13 %)
United Therapeutics Corporation
United Therapeutics Corporation
$259.68
$-4.55 (-1.72 %)
Zoetis Inc.
Zoetis Inc.
$165.18
$-3.06 (-1.82 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00